Exelixis
EXEL
#1637
Rank
NZ$17.90 B
Marketcap
$63.98
Share price
-0.38%
Change (1 day)
61.08%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of December 2024 : NZ$3.91 Billion

According to Exelixis's latest financial reports the company has NZ$3.91 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2024-12-31$NZ$3.97 B11.16%
2023-12-31$NZ$3.57 B-8.66%
2022-12-31$NZ$3.91 B21.1%
2021-12-31$NZ$3.23 B24.27%
2020-12-31$NZ$2.60 B4.03%
2019-12-31$NZ$2.50 B30.43%
2018-12-31$NZ$1.91 B378.36%
2017-12-31$NZ$0.40 B211.17%
2016-12-31$NZ$0.12 B-162.68%
2015-12-31$-NZ$0.21 Billion40.38%
2014-12-31$-NZ$0.15 Billion-281.82%
2013-12-31$NZ$80.6 M-77.63%
2012-12-31$NZ$0.36 B210.3%
2011-12-31$NZ$0.11 B-139.24%
2010-12-31$-NZ$0.3 Billion31.29%
2009-12-31$-NZ$0.23 Billion132.51%
2008-12-31$-NZ$96.95 Million-186.84%
2007-12-31$NZ$0.11 B-13.2%
2006-12-31$NZ$0.12 B53.43%
2005-12-31$NZ$83.82 M18.04%
2004-12-31$NZ$71.01 M-71.41%
2003-12-31$NZ$0.24 B-26.1%
2002-12-31$NZ$0.33 B-41.16%
2001-12-31$NZ$0.57 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
NZ$28.62 B 631.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$141.23 B 3,510.16%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$80.83 B 1,966.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$28.56 B 630.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$10.24 B 161.88%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$124.62 B 3,085.54%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$154.27 B 3,843.37%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$15.23 Million-100.39%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$50.28 M-98.71%๐Ÿ‡บ๐Ÿ‡ธ USA